Praxis Precision Medicines Inc.
Praxis Precision Medicines Reports Third Quarter 2024 Financial Results and Updates Corporate Presentation
Summary
On November 6, 2024, Praxis Precision Medicines, Inc. announced its financial results for the quarter ended September 30, 2024, revealing a net loss of $51.9 million. The company also updated its corporate presentation for investor meetings, detailing progress in its clinical-stage biopharmaceutical programs targeting central nervous system disorders. Praxis highlighted advancements in its Essential3 Phase 3 program for ulixacaltamide in essential tremor and positive topline results for the EMBOLD study for relutrigine in developmental and epileptic encephalopathies (DEEs). The company maintained its financial runway into 2027.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement